Repligen Corp (NAS:RGEN)
$ 168.71 -3.07 (-1.79%) Market Cap: 9.43 Bil Enterprise Value: 9.54 Bil PE Ratio: 674.84 PB Ratio: 4.78 GF Score: 93/100

Repligen Corp at William Blair Growth Stock Conference Transcript

Jun 11, 2020 / 02:20PM GMT
Release Date Price: $113.78 (-5.19%)
John Charles Kreger
William Blair & Company L.L.C., Research Division - Partner & Healthcare Services Analyst

Good morning, everyone. Welcome to our next session, which is Repligen, one of the most innovative companies in the bioprocessing space. I am John Kreger, I'm the research analyst at Blair that covers Repligen. I am required to inform you that you can obtain a complete list of research disclosures or potential conflicts of interest at williamblair.com.

Thanks for joining us. We're going to take the next 30 minutes to go through a fireside chat with Tony Hunt, the CEO of Repligen. Jon Snodgres, the CFO, is also on the line, and so he may chime in where appropriate. And last logistical comment I will make for all of you participating. There is a chat feature, so you are able to submit questions to me, and I will attempt to work them in time permitting.

So with that, let's kick it off.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot